Mechanism of Action
Broad Somatostatin Receptor Binding
Pasireotide binds SSTR1 (4x higher affinity vs octreotide), SSTR2 (comparable), SSTR3 (17x higher), and SSTR5 (40x higher). This broad profile enables suppression of corticotroph adenomas that predominantly express SSTR5, which first-generation analogs miss. SSTR3 activation also contributes to pro-apoptotic signaling in tumor cells.
ACTH Suppression in Cushing Disease
Corticotroph adenomas causing Cushing disease express predominantly SSTR5 and low levels of SSTR2. Pasireotide's high SSTR5 affinity enables direct acth/" class="wiki-internal-link">ACTH suppression, reducing cortisol production from the adrenal glands. This normalizes the HPA axis overactivity responsible for the metabolic, cardiovascular, and psychological sequelae of hypercortisolism.
Research Summary
Cushing's Disease
FDA ApprovedPhase 3 trial (n=162): 26% of patients achieved mean UFC normalization at month 6 on pasireotide SC; 34% showed >50% UFC reduction. Long-term data showed continued benefit at 12-24 months. SIGNIFOR LAR Phase 3: 31% normalization with monthly depot formulation. Efficacy advantage over other medical options (cabergoline, ketoconazole) in direct comparisons.
Acromegaly
FDA ApprovedPhase 3 PAOLA trial: Pasireotide LAR achieved GH control (<2.5 mcg/L) in 48% and IGF-1 normalization in 38% of lanreotide-resistant patients. Among somatostatin analog-naive patients, normalization rates of 31-35%, modestly higher than lanreotide/octreotide. Particularly valuable in partial responders to first-generation analogs.
Calculate your Pasireotide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Cushing's disease (SC) | 0.3 mg SC BID, escalate to 0.6 mg BID at 2 months if UFC not normalized; max 0.9 mg BID | Twice daily | Subcutaneous |
| Cushing's disease (LAR) | 10 mg IM monthly, titrate to 30 or 40 mg based on UFC response | Monthly | Intramuscular |
| Acromegaly (LAR) | 40 mg IM monthly; may reduce to 20 mg in controlled patients | Monthly | Intramuscular |
Monitor fasting glucose/HbA1c closely; hyperglycemia is the most clinically impactful adverse effect of pasireotide.
Interactions
Safety Profile
Hyperglycemia is the most significant adverse effect, occurring in 57-73% of patients and requiring antidiabetic treatment initiation in most. The mechanism involves SSTR5-mediated inhibition of both insulin and incretin secretion. GI effects (diarrhea, nausea, abdominal pain) common but usually mild. QTc prolongation (mean 13-18 msec) requires baseline ECG and monitoring. Gallbladder effects (cholelithiasis) similar to other somatostatin analogs. Liver enzyme elevations (ALT/AST) occur; monitor LFTs. Bradycardia and cardiac conduction abnormalities possible.
References
- [1]Colao A, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012;366(10):914-924.
- [2]Gadelha MR, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA). Lancet Diabetes Endocrinol. 2014;2(11):875-884.